# Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

> **NCT02049541** · PHASE1 · COMPLETED · sponsor: **Kami Maddocks, MD** · enrollment: 18 (actual)

## Conditions studied

- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Nodal Marginal Zone B-cell Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Splenic Marginal Zone Lymphoma
- Waldenström Macroglobulinemia

## Interventions

- **DRUG:** PI3K inhibitor BKM120
- **BIOLOGICAL:** rituximab
- **OTHER:** Pharmacodynamics
- **OTHER:** Correlative studies

## Key facts

- **NCT ID:** NCT02049541
- **Lead sponsor:** Kami Maddocks, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-21
- **Primary completion:** 2018-09-12
- **Final completion:** 2019-04-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049541, "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02049541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*